A poor prognostic metastatic nongestational choriocarcinoma of the ovary: a case report and the literature review.
BEP therapy
Pure ovarian nongestational choriocarcinoma
Short tandem repeat analysis
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
06
10
2020
accepted:
13
04
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Pure ovarian choriocarcinoma can be gestational or nongestational in origin. Nongestational pure ovarian choriocarcinoma is extremely rare and the prognosis is thought to be worse than that of the gestational type in patients with metastatic disease. We present a case of metastatic pure ovarian choriocarcinoma with poor prognosis in which the origin was identified as nongestational by DNA short tandem repeat (STR) analysis. A nulliparous woman in her thirties with metastatic choriocarcinoma was referred to our hospital after initial treatment proved unsuccessful. Two months earlier, she had undergone brain tumor resection and histological examination confirmed choriocarcinoma. Serum human chorionic gonadotropin (hCG) concentration at initial diagnosis was 5030 IU/L. Two cycles of a combination chemotherapy regimen of methotrexate, etoposide, and actinomycin-D (MEA therapy), which is commonly used for gestational choriocarcinoma, was administered. However, the disease could not be controlled. Imaging modalities at presentation revealed tumor present in the left ovary and left lung, but not in the uterus, which led us think that the choriocarcinoma was nongestational. Bleomycin, etoposide, and cisplatin (BEP therapy) which is commonly used for nongestational choriocarcinoma (malignant germ cell tumor) and surgical resection of the uterus, bilateral ovaries, and an affected part of the left lung led to the nadir level of hCG, but the tumor relapsed and levels of hCG again increased. To investigate the origin of choriocarcinoma, we performed DNA STR analysis of tumor cells and oral mucosal cells. Analysis revealed the origin of the choriocarcinoma as nongestational, as the genotype of tumor cells entirely corresponded with that of oral mucosal cells. BEP therapy and chemotherapy regimens administered for nongestational choriocarcinoma and gestational choriocarcinoma proved ineffective, and the patient died 21 months after diagnosis of metastatic choriocarcinoma. Metastaic nongestational pure choriocarcinoma of ovary is an extremely rare and an aggressive disease, frequently resulting in poor outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Pure ovarian choriocarcinoma can be gestational or nongestational in origin. Nongestational pure ovarian choriocarcinoma is extremely rare and the prognosis is thought to be worse than that of the gestational type in patients with metastatic disease. We present a case of metastatic pure ovarian choriocarcinoma with poor prognosis in which the origin was identified as nongestational by DNA short tandem repeat (STR) analysis.
CASE PRESENTATION
METHODS
A nulliparous woman in her thirties with metastatic choriocarcinoma was referred to our hospital after initial treatment proved unsuccessful. Two months earlier, she had undergone brain tumor resection and histological examination confirmed choriocarcinoma. Serum human chorionic gonadotropin (hCG) concentration at initial diagnosis was 5030 IU/L. Two cycles of a combination chemotherapy regimen of methotrexate, etoposide, and actinomycin-D (MEA therapy), which is commonly used for gestational choriocarcinoma, was administered. However, the disease could not be controlled. Imaging modalities at presentation revealed tumor present in the left ovary and left lung, but not in the uterus, which led us think that the choriocarcinoma was nongestational. Bleomycin, etoposide, and cisplatin (BEP therapy) which is commonly used for nongestational choriocarcinoma (malignant germ cell tumor) and surgical resection of the uterus, bilateral ovaries, and an affected part of the left lung led to the nadir level of hCG, but the tumor relapsed and levels of hCG again increased. To investigate the origin of choriocarcinoma, we performed DNA STR analysis of tumor cells and oral mucosal cells. Analysis revealed the origin of the choriocarcinoma as nongestational, as the genotype of tumor cells entirely corresponded with that of oral mucosal cells. BEP therapy and chemotherapy regimens administered for nongestational choriocarcinoma and gestational choriocarcinoma proved ineffective, and the patient died 21 months after diagnosis of metastatic choriocarcinoma.
CONCLUSION
CONCLUSIONS
Metastaic nongestational pure choriocarcinoma of ovary is an extremely rare and an aggressive disease, frequently resulting in poor outcome.
Identifiants
pubmed: 33888146
doi: 10.1186/s13048-021-00810-3
pii: 10.1186/s13048-021-00810-3
pmc: PMC8063363
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Subventions
Organisme : Aichi Cancer Research Foundation
ID : Aichi Cancer Research Foundation
Références
Obstet Gynecol. 1976 Nov;48(5):579-89
pubmed: 185553
Hum Pathol. 2016 Jun;52:92-100
pubmed: 26980014
Obstet Gynecol. 2003 Nov;102(5 Pt 1):991-4
pubmed: 14672475
Cancer. 1985 Nov 1;56(9):2321-5
pubmed: 3902208
Cancer Lett. 1996 Jun 24;104(1):27-30
pubmed: 8640741
Gynecol Oncol. 2003 Jun;89(3):540-2
pubmed: 12798727
Int J Gynecol Pathol. 2012 Jul;31(4):364-8
pubmed: 22653351
J Reprod Med. 2011 Nov-Dec;56(11-12):511-4
pubmed: 22195336
Gynecol Oncol Case Rep. 2014 Apr 18;9:3-6
pubmed: 24944881
J Clin Oncol. 1990 Apr;8(4):715-20
pubmed: 1690272
Gynecol Oncol. 2017 Jan;144(1):200-207
pubmed: 27743739
Placenta. 2009 Sep;30(9):816-20
pubmed: 19647314
Am J Obstet Gynecol. 2014 Jul;211(1):e1-3
pubmed: 24732004
Pathol Int. 2006 Oct;56(10):613-6
pubmed: 16984618
Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):113-4
pubmed: 20561742
Am J Surg Pathol. 2017 Dec;41(12):1593-1606
pubmed: 28877059
Rare Tumors. 2013 Jun 13;5(2):89-92
pubmed: 23888224
Am J Obstet Gynecol. 2011 Jan;204(1):11-8
pubmed: 20739008
Mol Ecol. 2003 Mar;12(3):563-84
pubmed: 12675814
J Neurosci Rural Pract. 2015 Oct-Dec;6(4):578-81
pubmed: 26752905
Can Med Assoc J. 1979 Apr 7;120(7):830-1
pubmed: 570878
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):254-8
pubmed: 17291262
Taiwan J Obstet Gynecol. 2016 Dec;55(6):881-885
pubmed: 28040140
J Clin Oncol. 1994 Apr;12(4):701-6
pubmed: 7512129
J Obstet Gynaecol Res. 2011 Oct;37(10):1493-6
pubmed: 21599798
Postgrad Med J. 1985 Aug;61(718):757-8
pubmed: 4041040
J Gynecol Oncol. 2009 Sep;20(3):192-4
pubmed: 19809555
Lancet. 2010 Aug 28;376(9742):717-29
pubmed: 20673583
Hum Pathol. 2014 Apr;45(4):717-24
pubmed: 24485845
Forensic Sci Int Genet. 2015 Sep;18:100-17
pubmed: 25866376